Free Trial

Galmed Pharmaceuticals (GLMD) Competitors

Galmed Pharmaceuticals logo
$1.77 -0.06 (-3.23%)
As of 09:36 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

GLMD vs. TRIB, ATHA, BGXX, BCDA, EQ, SNSE, LPTX, BTAI, XFOR, and PHXM

Should you be buying Galmed Pharmaceuticals stock or one of its competitors? The main competitors of Galmed Pharmaceuticals include Trinity Biotech (TRIB), Athira Pharma (ATHA), Bright Green (BGXX), BioCardia (BCDA), Equillium (EQ), Sensei Biotherapeutics (SNSE), Leap Therapeutics (LPTX), BioXcel Therapeutics (BTAI), X4 Pharmaceuticals (XFOR), and PHAXIAM Therapeutics (PHXM). These companies are all part of the "pharmaceutical products" industry.

Galmed Pharmaceuticals vs. Its Competitors

Galmed Pharmaceuticals (NASDAQ:GLMD) and Trinity Biotech (NASDAQ:TRIB) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation and risk.

76.1% of Galmed Pharmaceuticals shares are held by institutional investors. Comparatively, 79.0% of Trinity Biotech shares are held by institutional investors. 19.8% of Galmed Pharmaceuticals shares are held by company insiders. Comparatively, 8.2% of Trinity Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Trinity Biotech had 2 more articles in the media than Galmed Pharmaceuticals. MarketBeat recorded 2 mentions for Trinity Biotech and 0 mentions for Galmed Pharmaceuticals. Galmed Pharmaceuticals' average media sentiment score of 0.00 equaled Trinity Biotech'saverage media sentiment score.

Company Overall Sentiment
Galmed Pharmaceuticals Neutral
Trinity Biotech Neutral

Galmed Pharmaceuticals has higher earnings, but lower revenue than Trinity Biotech. Trinity Biotech is trading at a lower price-to-earnings ratio than Galmed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Galmed PharmaceuticalsN/AN/A-$7.52M-$16.66-0.11
Trinity Biotech$61.56M0.21-$31.79M-$2.82-0.26

Galmed Pharmaceuticals has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500. Comparatively, Trinity Biotech has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500.

Galmed Pharmaceuticals has a net margin of 0.00% compared to Trinity Biotech's net margin of -51.64%. Trinity Biotech's return on equity of 0.00% beat Galmed Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Galmed PharmaceuticalsN/A -32.21% -28.59%
Trinity Biotech -51.64%N/A -27.43%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Galmed Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Trinity Biotech
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

Trinity Biotech beats Galmed Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

Get Galmed Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for GLMD and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GLMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GLMD vs. The Competition

MetricGalmed PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$2.94M$2.43B$5.53B$9.02B
Dividend YieldN/A1.78%5.22%3.99%
P/E Ratio-0.119.1527.8120.25
Price / SalesN/A680.43429.10119.26
Price / CashN/A21.7726.2128.59
Price / Book0.184.558.025.65
Net Income-$7.52M$31.26M$3.18B$249.15M
7 Day Performance-4.02%2.98%2.88%2.91%
1 Month Performance16.95%3.46%1.66%4.11%
1 Year Performance-52.59%0.77%34.25%20.98%

Galmed Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GLMD
Galmed Pharmaceuticals
N/A$1.77
-3.2%
N/A-51.5%$2.94MN/A-0.1120
TRIB
Trinity Biotech
0.51 of 5 stars
$0.65
-0.3%
N/A-65.3%$11.77M$61.56M-0.23480Gap Up
ATHA
Athira Pharma
2.4861 of 5 stars
$0.30
+2.4%
$11.25
+3,625.2%
-87.0%$11.52MN/A-0.1540Gap Down
BGXX
Bright Green
N/AN/AN/AN/A$11.47MN/A-1.002Gap Down
BCDA
BioCardia
3.9935 of 5 stars
$1.95
-9.3%
$25.00
+1,182.1%
-29.0%$11.13M$60K-0.8440Positive News
Gap Up
EQ
Equillium
1.8074 of 5 stars
$0.32
+1.7%
$3.00
+851.8%
-51.9%$11.07M$41.10M-0.8140Gap Up
SNSE
Sensei Biotherapeutics
4.1958 of 5 stars
$8.58
-1.2%
$90.00
+949.0%
-27.1%$10.94MN/A-0.3740Gap Down
LPTX
Leap Therapeutics
1.4132 of 5 stars
$0.30
+13.5%
$3.38
+1,036.7%
-85.6%$10.84MN/A-0.1740
BTAI
BioXcel Therapeutics
4.507 of 5 stars
$1.81
+2.3%
$42.60
+2,253.6%
-88.3%$10.72M$2.27M-0.1390Gap Up
XFOR
X4 Pharmaceuticals
4.6685 of 5 stars
$1.90
+3.8%
$72.33
+3,707.0%
-88.1%$10.59M$2.56M0.8980High Trading Volume
PHXM
PHAXIAM Therapeutics
N/A$3.10
flat
N/AN/A$10.58M$32.66M0.0049

Related Companies and Tools


This page (NASDAQ:GLMD) was last updated on 7/7/2025 by MarketBeat.com Staff
From Our Partners